Disclosures

The speakers of each symposium have been asked to disclose any relationships that could be perceived as a conflict of interest. Disclosures are listed alphabetically by symposium supporter.

Allos Therapeutics, Inc., and Seattle Genetics, Inc.

Diagnostic and Therapeutic Overview of T-Cell Lymphoma: Past, Present, and Future 

  • Christian Gisselbrecht, MD, Hôpital Saint-Louis, Paris, France: consultant for Allos Therapeutics, Roche, Seattle Genetics, CTI, and Janssen; contracted research for Roche.
  • Youn H. Kim, MD, Stanford Cancer Institute, Stanford School of Medicine, Stanford, CA: contracted research for Allos Therapeutics, Kyowa, Merck, Seattle Genetics, Tenx, and Youpon; honoraria from Celgene Corporation and Merck; consultant for Allos Therapeutics, Celgene Corporation, Eisai, Kyowa, Millennium: The Takeda Oncology Company, and Seattle Genetics; royalty from UpToDate, Inc.
  • Richard L. Piekarz, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD: indicated no conflicts of interest.
  • Andrei R. Shustov, MD, Seattle Cancer Care Alliance, Seattle, WA: honoraria from Allos Therapeutics and Celgene Corporation.
  • Anas Younes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX: research funding from Genentech BioOncology, SBIO, Syndax, Novartis, and sanofiaventis; honoraria from Seattle Genetics and sanofi-aventis.
  • Jasmine Zain, MD, NYU Clinical Cancer Center, New York, NY: consultant/honoraria from Allos Therapeutics.

back to top
 

Amgen, Inc.

The Care of Immune Thrombocytopenia (ITP) Patients: Advancing Quality of Life and Improving Treatment Outcomes 

  • James B. Bussel, MD, Weill Cornell Medical College, New York, NY: consultant for Amgen, GlaxoSmithKline, Ligand, Shionogi, Eisai, Cangene, Genzyme, IgG of America, Immunomedics, Sysmex, and Portola.
  • David J. Kuter, MD, DPhil, Massachusetts General Hospital, Harvard Medical School, Boston, MA: consultant for Amgen, GlaxoSmithKline Oncology, and Shionogi.
  • Jenny McDade, DO, St. Jude Children’s Research Hospital, Memphis, TN: consultant for Cangene.
  • Douglas B. Cines, MD, University of Pennsylvania, Philadelphia, PA: consultant for GlaxoSmithKline Oncology and Amgen.
  • Terry B. Gernsheimer, MD, University of Washington, Seattle, WA: consultant for GlaxoSmithKline Oncology, Amgen, Cangene, Baxter, Scope Medical, and Shionogi.
  • Keith B. McCrae, MD, Cleveland Clinic Lerner College of Medicine, Cleveland, OH: consultant for Amgen and GlaxoSmithKline Oncology.
  • Vinod Pullarkat, MD, University of Southern California, Los Angeles, CA: consultant for Amgen Inc. and GlaxoSmithKline Oncology.

back to top
 

Aplastic Anemia & MDS International Foundation, Inc.

Successes in Bone Marrow Failures 

  • David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA: consultant for Celgene Corporation and Janssen Cilag.
  • Ramon Tiu, MD, PhD, Cleveland Clinic, Cleveland, OH: consultant for Celgene Corporation and Incyte.
  • Valeria Santini, MD, University of Florence, Florence, Italy: consultant for Celgene Corporation and Janssen Cilag.
  • Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, TX: indicated no conflicts of interest.
  • Antonio Risitano, MD, PhD, Federico II University Medical School, Naples, Italy: indicated no conflicts of interest.
  • Bart Scott, MD, Fred Hutchinson Cancer Center, Seattle, WA: indicated no conflicts of interest.

back to top
 

CLL Global Research Foundation

The Road to a Cure of Chronic Lymphocytic Leukemia (CLL) 

  • Susan O'Brien, MD, The University of Texas MD Anderson Cancer Center, Houston, TX: advisory committee for Astra Zeneca and Pharmacyclics; consultant for Calistoga, Celgene Corporation, Cephalon Oncology, Genzyme, GlaxoSmithKline, MorphoSys, Pfizer, ad Seattle Genetics, Inc; research support for Calistoga, Genentech BioOncology, Pharmacyclics, and Talon.
  • Stefan Stilgenbauer, MD, University of Ulm, Ulm, Germany: research for/honoraria from Amgen Inc., Bayer, Boehringer Ingelheim, Celgene Corporation, Genzyme, GlaxoSmithKline Oncology, Mundipharma, Roche, and sanofi-aventis.
  • John Gribben, MD, Barts Cancer Center of Excellence/The London School of Medicine, London, United Kingdom: honoraria from Roche Pharmaceuticals, GlaxoSmithKline Oncology, Celgene Corporation, and Mundipharma; research funding from National Institutes of Health, Cancer Research UK, MRC, and CLL Global Research Foundation.
  • William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX: consultant for Genentech BioOncology and Celgene Corporation; research funding from GlaxoSmithKline Oncology and Abbott.
  • William Plunkett, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX: indicated no conflicts of interest.
  • Carlo Croce, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH: indicated no conflicts of interest.

back to top
 

Foundation for Women & Girls with Blood Disorders

Gynecologic Challenges for Hematologists: Tools for Optimal Management of Women and Adolescent Girls with Blood Disorders 

  • Andra James, MD, Duke University Medical Center, Durham, NC: honoraria from CSL Behring, Grifols, and Talecris; research funding from CSL Behring.
  • Roshni Kulkarni, MD, Michigan State University, East Lansing, MI: consultant/speaker for CSL Behring, Baxter, and Novo Nordisk.
  • Jennifer E. Dietrich, MD, Baylor College of Medicine, Houston, TX: honoraria from/speaker for Merck and CSL Behring.
  • Peter Kouides, MD, Lipson Cancer and Blood Center, Rochester General Hospital, Rochester NY: honoria from/advisory board for CSL Behring, Ferring Pharmaceuticals, and Grifols.
  • Kim Smith-Whitley, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA: indicated no conflicts of interest.

back to top
 

Grifols USA, LLC

Factor VIII Inhibitors in Hemophilia A: Contemporary Perspectives 

  • Jan Astermark, MD, PhD, Skåne University Hospital, Malmö, Sweden: research support from Grifols, Baxter, Bayer, Octapharma, and CSL Behring Foundation; speaker/advisory board for Baxter, Bayer Novo Nordisk, CSL Behring Foundation, and Biovitrum.
  • Nadia P. Ewing, MD, City of Hope, Duarte, CA: speaker for Baxter, Grifols, Novo Nordisk, and Talecris; research support from Bayer and Inspiration; consultant for Baxter, Biogen Idec, CSL Behring Foundation, Grifols, Novo Nordisk, Octapharma, Talecris, and Wyeth.
  • Margaret A. Heisel Kurth, MD, Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN: research support from Grifols.
  • Pier M. Mannucci, MD, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy: consultant for Baxter, Bayer, Grifols, Kedrion, Novo Nordisk, and Pfizer.
  • Kathleen P. Pratt, PhD, Puget Sound Blood Center, Seattle, WA: research support from Bayer and CSL Behring Foundation.
  • Guy Young, MD, University of Southern California, Los Angeles, CA: advisory board/speaker for Baxter and Novo Nordisk.

back to top 

Incyte Corporation

Myelofibrosis: An Old Disease with new Developments 

  • Kenneth Kaushansky, MD, Stony Brook University, Stony Brook, NY: consultant for Ligand Pharmaceuticals.
  • Jean-Jacques Kiladjian, MD, PhD, Hôpital Saint-Louis and Université de Paris, Paris, France: consultant for Novartis Pharmaceuticals, Celgene Corporation, and YM Biosciences.
  • Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX: consultant for Incyte, Celgene Corporation, AstraZeneca, Lilly Oncology, SBIO, Geron, Gilead, Roche Pharmaceuticals, Bristol-Myers Squibb, NS-Pharma, AB Science, and Exelxis.
  • John McCarty, MD, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA: consultant for Allos Therapeutics.
  • Ruben Mesa, MD, Mayo Clinic, Scottsdale, AZ: consultant for Incyte, SBIO, AstraZeneca, Telik, Lilly Oncology, and Celgene Corporation.

back to top
 

International Myeloma Foundation (IMF)

Myeloma Questions and Controversies: New Developments in 2011 That Impact Diagnosis, Prognosis, and Treatment 

  • Brian G.M. Durie, MD, Aptium Oncology, Inc., Los Angeles, CA: consultant for Celgene and Millennium: The Takeda Oncology Company.
  • Philipe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France: consultant for Celgene Corporation and Janssen-Cilag.
  • Robert Z. Orlowski, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX: consultant for Celgene Corporation, Millennium: The Takeda Oncology Company, and Proteolix.
  • Antonio Palumbo, MD, University of Torino, Azienda Ospedaliero-Universitaria San Giovanni Battista, Torino, Italy: honoraria from Amgen, Celgene Corporation, Janssen-Cilag, and Merck; advisory board for Celgene Corporation and Janssen-Cilag.
  • S. Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN: indicated no conflicts of interest.
  • Jesús F. San-Miguel, MD, PhD, University of Salamanca, Salamanca, Spain: consultant for Celgene Corporation, Millennium: The Takeda Oncology Company, and Ortho Biotech.

back to top 

MDS Foundation

Next-Generation Approaches for Evaluation and Treatment of Myelodysplastic Syndromes (MDS) 

  • Peter Greenberg, MD, Stanford University Medical Center, Palo Alto, CA: indicated no conflicts of interest.
  • Alan List, MD, H. Lee Moffitt Cancer Center, Tampa, FL: indicated no conflicts of interest.
  • Jacqueline Boultwood, MD, University of Oxford, Oxford, United Kingdom: indicated no conflicts of interest.
  • Ghulam Mufti, DM, King’s College Hospital, London, United Kingdom: indicated no conflicts of interest.
  • Juliet N. Barker, MD, Memorial Sloan Kettering Cancer Center, New York, NY: indicated no conflicts of interest.

back to top 

Millennium: The Takeda Oncology Company, Celgene Inc., Allos Therapeutics, and The Leukemia & Lymphoma Society

Epigenetics in Hematologic Malignancies: Pathogenesis and Therapy 

  • Stephen B. Baylin, MD, The Johns Hopkins University, Baltimore, MD: consultant for MDxHealth, BioNumerik Pharmaceuticals, and Constellation Pharmaceuticals.
  • James E. Bradner, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA: patent/stock in Shape Pharmaceuticals, Inc. and Acetylon Pharmaceuticals, Inc.
  • Jonathan D. Licht, MD, Feinberg School of Medicine, Northwestern University, Evanston, IL: royalty from Abcam and EMD; bioscience and research for Epizyme Inc.
  • Ross L. Levine, MD, Memorial Sloan-Kettering Cancer Center, New York, NY: research for Agios.
  • Jean-Pierre Issa, MD, The University of Texas MD Anderson Center, Houston, TX: consultant for GlaxoSmithKline Oncology and SYNDAX; research for Merck, Eisai, and Celgene Corporation; honoraria from Celgene Corporation, Novartis, and Johnson & Johnson.

back to top
 

Multiple Myeloma Research Foundation, Celgene Corporation, Lilly USA, LLC, Novartis Pharmaceuticals Corporation, and Millennium Pharmaceuticals, Inc.

Current Clinical Controversies and Future Research Priorities for the Treatment of Multiple Myeloma 

  • Paul G. Richardson, MD, Dana-Farber Cancer Institute, Boston, MA: advisory board for Millennium: The Takeda Oncology Company, Celgene Corporation, Novartis Pharmaceuticals, Johnson & Johnson, and Bristol-Myers Squibb.
  • Herve Avet-Loiseau, MD, PhD, University Hospital of Nantes, Nantes, France: consultant for Celgene Corporation and Janssen-Cilag.
  • Andrzej J. Jakubowiak, MD, PhD, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI: consultant for Millennium: The Takeda Oncology Company; honoraria from Millennium: The Takeda Oncology Company, Celgene Corporation, Centocor Ortho Biotech, Exellxis, and Bristol- Myers Squibb.
  • Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain: honoraria from Janssen, Celgene Corporation, and Novartis Pharmaceuticals.
  • S. Vincent Rajkumar, MD: indicated no conflicts of interest.
  • Philip McCarthy Jr., MD, Roswell Park Cancer Institute, Buffalo, NY: honoraria from Celgene Corporation and Onyx.

back to top
 

Mundipharma International Limited, Cephalon Oncology, Millennium: The Takeda Oncology Company, Celgene Corporation, and Genentech BioOncology/Biogen Idec.

International Hematologic Oncology Tumor Board: Practical Perspectives on Current Challenging Cases of Non-Hodgkin Lymphoma (Part One of a Two-Part Series) 

  • Martin Dreyling, MD, PhD, University Hospital Campus Grosshadern, Munich, Germany: advisory board and speaking honoraria for Celgene Corporation, Janssen, Mundipharma International Ltd, Pfizer, and Roche Pharmaceuticals; clinical trial support for Celgene Corporation, Janssen, Mundipharma International Ltd., and Roche Pharmaceuticals; paid research for GlaxoSmithKline Oncology and Roche Pharmaceuticals.
  • Alessandra Ferrajoli, MD, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX: paid research for Celgene Corporation, Genentech BioOncology, and GlaxoSmithKline Oncology.
  • Stephanie A. Gregory, MD, Rush University Medical Center, Chicago, IL: advisory board for Amgen Inc., Cephalon Oncology, Genentech BioOncology, Novartis Pharmaceuticals, and Spectrum Pharmaceuticals; speakers bureau for Cephalon Oncology.
  • Julie M. Vose, MD, The Nebraska Medical Center, Omaha, NE: paid research for Allos Therapeutics, AstraZeneca, Bristol-Myers Squibb, Celgene Oncology, Exelixis Inc., Genentech BioOncology, Genzyme, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals, Pharmacyclics Inc., S*BIO Pte Ltd., US Biotest Inc.
  • Andrew D. Zelenetz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY: consultant for Celgene Corporation, Cell Therapeutics Inc., Cephalon Oncology, and Genentech BioOncology, GlaxoSmithKline Oncology; paid  research for Amgen, Inc., Genentech BioOncology, and GlaxoSmithKline Oncology.
  • Pier Luigi Zinzani, MD, Institute of Hematology "Seragnoli," University of Bologna, Bologna, Italy: advisory board for Celgene Corporation, Genzyme, and Millennium: The Takeda Oncology Company.

back to top
 

Mundipharma International Limited, Cephalon Oncology, Millennium: The Takeda Oncology Company, Celgene Corporation, and Genentech BioOncology/Biogen Idec.

International Hematologic Oncology Tumor Board: Practical Perspectives on Current Challenging Cases of Multiple Myeloma (Part Two of a Two-Part Series) 

  • Michele Cavo, MD, Institute of Hematology and Medical Oncology "Seragnoli," Bologna University School of Medicine, S Orsola's University Hospital, Bologna, Italy: consulting fees, honoraria, and speakers bureau for Celgene Corporation, Janssen-Cilag EMEA, Millennium: The Takeda Oncology Company, and Novartis Pharmaceuticals Corporation.
  • Morie A. Gertz, MD, Department of Medicine, Mayo Clinic, Rochester, MN: advisory committee for Celgene Corporation and Millennium: The Takeda Oncology Company.
  • Carol Ann Huff, MD, The Johns Hopkins University, Baltimore, MD: advisory committee for Amgen, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Pharmaceuticals, and Onyx Pharmaceuticals Inc.; paid research for Bristol-Myers Squibb Company and Geron.
  • Nikhil C. Munshi, MD, Dana-Farber Cancer Institute, Boston, MA: advisory committee for Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals Inc.; consulting agreements with Celgene Corporation, Millennium: The Takeda Oncology Company, and Novartis Pharmaceuticals Corporation.
  • David S. Siegel, MD, PhD, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ: advisory committee for Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.; speakers bureau for Celgene Corporation, Millennium: The Takeda Oncology Company.
  • Pieter Sonneveld, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands: advisory committee for Celgene Corporation, Janssen, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals Inc.; paid research for Celgene Corporation and Janssen Cilag.

back to top
 

National Marrow Donor Program

Recent Advances in Hematopoietic Cell Transplantation: Evidence-Based Decision Making 

  • Dennis Confer, MD, National Marrow Donor Program, Minneapolis, MN: indicated no conflicts of interest.
  • John Wingard, MD, Shands Cancer Hospital, University of Florida, Gainesville, FL: honoraria from Gamida, Vical, Astellas/Basilen, Athersys, Pfizer, and Merck.
  • Willis Navarro, MD, National Marrow Donor Program, Minneapolis, MN: indicated no conflicts of interest.
  • Helen Heslop, MD, Baylor College of Medicine, Houston, TX; research support from Hemaquert and Cell Medicine.

back to top
 

Ortho-McNeil Janssen Scientific Affairs, LLC

Oral Anticoagulant Therapy in Thromboembolic Disease: The Key Questions 

  • Kenneth A. Bauer, MD, Harvard Medical School, Boston, MA: consultant for Bristol-Myers Squibb and Johnson & Johnson.
  • Alex C. Spyropoulos, MD, Thrombosis Center, Hamilton Hospital, Hamilton, Ontario, Canada: consultant for Eisai, Inc., Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, and Johnson & Johnson.
  • Jessica L. Mega, MD, Harvard Medical School, Boston, MA: research for Bayer Healthcare, Bristol-Myers Squibb, Eli Lilly and Company, Daiichi Sankyo, Johnson & Johnson, National Institutes of Health, and sanofi-aventis; research supplies from Accumentrics and Nanosphere; consultant for/honoraria from AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, and sanofi-aventis.
  • Alexander G. G. Turpie, MD, McMaster University, Hamilton, Ontario, Canada: advisory board for Bristol-Myers Squibb, Daiichi Sankyo, sanofi-aventis, and Schering-Plough; consultant for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Portola, Pfizer, sanofiaventis, Millennium: The Takeda Oncology Company, and the Medicines Company.
  • Jeffrey I. Weitz, MD, McMaster University, Hamilton, Ontario, Canada: advisory board for Bristol-Myers Squibb, Daiichi Sankyo, sanofi-aventis, and Schering-Plough; consultant for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Portola, Pfizer, sanofi-aventis, Millennium: The Takeda Oncology Company, and the Medicines Company.

back to top
 

Otsuka America Pharmaceutical, Inc.

Decisions in Community Hematology: Planning Ahead for Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphoma 

  • Robert Soiffer, MD, Dana-Farber Cancer Institute, Boston, MA: consultant for Miltenyi Biotech, Genzyme, and Frensenius NA.
  • Koen van Besien, MD, University of Chicago, Chicago, IL: research support from Genzyme, Otsuka, and Therakos; consultant for Genzyme, Otsuka, Teva Pharmaceuticals, and Therakos.
  • Ginna Laport, MD, Stanford University Medical Center, Palo Alto, CA: indicated no conflicts of interest.
  • Philip Bierman, MD, University of Nebraska Medical Center, Omaha, NE: advisory board for Seattle Genetics; research for Otsuka and Serono.
  • Ajay Gopal, MD, Fred Hutchinson Cancer Research Center, Seattle, WA: research support from Lymphoma Research Foundation, Leukemia & Lymphoma Society, CLL Topics, GlaxoSmithKline Oncology, Merck, Seattle Genetics, Cephalon Oncology, Lilly and Company, Piramal, Spectrum, Biogen Idec, Pfizer, BioMarin, S*Bio, and Abbott Laboratories.

back to top
 

Seattle Genetics, Inc., Kyowa Hakko Kirin, Spectrum Pharmaceuticals, Ziopharm Oncology, and Millennium: The Takeda Oncology Company

Clinical Controversies in T-Cell Lymphoma 

  • Francine M. Foss, MD, Yale Cancer Center, New Haven, CT: consultant for Celgene Corporation, Allos Therapeutics, Eisai, Merck, and Bayer.
  • James O. Armitage, MD, University of Nebraska Medical Center, Omaha, NE: consultant for Ziopharm, Eisai, and Seattle Genetics.
  • Madeleine Duvic, MD, The University of Texas MD Anderson Cancer Center, Houston, TX: consultant for Allos Therapeutics, Biocryst, Celgene Corporation, Cyclacel, Dermatex, Eisai, Eli Lilly and Company, Genmab, Hana Biosciences, Hoffman-LaRoche, Kyowa Hakko Kirin Pharmaceuticals, Merck, Millennium: The Takeda Oncology Company, NAAF, National Institutes of Health, Ortho Biotech, MSK, P4 Healthcare, PeerDirect, Pfizer, Quintiles Pharma, Seattle Genetics, Memorial Sloan-Kettering Cancer Center, Spectrum Pharmaceuticals, Therakos, Topotarget, Upside Endeavors LLC, Vertex, and Yapon Therapeutics.
  • Lauren C. Pinter-Brown, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA: consultant for Allos Therapeutics and Kyowa Hakko Kirin.
  • Kensei Tobinai, MD, PhD, National Cancer Center Hospital, Tokyo, Japan: indicated no conflicts of interest.
  • Steven M. Horwitz, MD, Memorial Sloan-Kettering Cancer Center, New York, NY: consultant for Allos Therapeutics, Genzyme, Novartis Pharmaceuticals, Seattle Genetics, Millennium: The Takeda Oncology Company, Bristol-Myers Squibb, Celgene Corporation, and Merck.

back to top
 

Wallace H. Coulter Foundation

Innovations in Laboratory Medicine: Therapeutic Assessment 

  • Shannon M. Bates, MDCM, McMaster University, Hamilton, Ontario, Canada: research support from Stago.
  • Charles S. Eby, MD, Washington University School of Medicine, St. Louis, MO: indicated no conflicts of interest.
  • Dorothy M. (Adcock) Funk, MD, Esotorix, Inc., Phoenix, AZ: speaker for Siemens and BoMerieux.
  • Richard D. Press, MD, PhD, Oregon Health & Science University, Portland, OR: indicated no conflicts of interest.
  • Garry P. Nolan, PhD, Stanford School of Medicine, Stanford, CA: consultant for Becton Dickinson Biosciences and DVS Sciences; stock in DVS Sciences; applied patent for SPADE algorithm.

back to top